Skip to main content
SpringerLink
Log in

Safety and Efficacy of Oral Nonsteroidal Anti-Inflammatory Drugs in Patients with Rheumatoid Arthritis

A Six-Month Randomised Study

  • Original Research Article
  • Published:
Clinical Drug Investigation Aims and scope Submit manuscript

Abstract

Objective: To monitor the safety and efficacy profile of long-term treatment with diclofenac, nabumetone, meloxicam and celecoxib in patients with rheumatoid arthritis.

Design and methods: This randomised, prospective clinical trial included a total of 461 subjects (313 females and 148 males) with clinically diagnosed rheumatoid arthritis. Their average age was 46.9 ± 14.4 years (range 20–69 years), and the average disease duration was 1333.7 ± 992.85 days. Subjects were randomly assigned daily administration of one of the following: diclofenac 75–100mg, meloxicam 15mg, nabumetone l000mg or celecoxib 200mg. During the 6-month treatment period, a monthly patient interview was conducted to evaluate drug efficacy and safety.

Results: 407 subjects successfully completed the 6-month treatment. Sixteen patients (12.2%) withdrew from the diclofenac group, 16 (12.2%) from the nabumetone group, 17 (11.8%) from the meloxicam group and five (9.1%) from the celecoxib group. Most withdrawals occurred during the first 3 months of treatment. Reasons for withdrawals in the first three groups were lack of efficacy (44.9%) and adverse effects (38.8%). For the celecoxib group, high cost (80%) was the main reason for withdrawal. Adverse drug reactions to NSAIDs mostly occurred at an early stage of treatment, with an incidence rate of 31.9% for the diclofenac group, 19.9% for the nabumetone group, 25.2% for the meloxicam group, and 7.27% for the celecoxib group. Clinical efficacy rates for the four NSAIDs were positively related to the length of treatment. During the first 4 months, diclofenac, meloxicam and celecoxib showed better efficacy than nabumetone. There were no significant differences in efficacy during the fifth and sixth months. The overall 6-month effectiveness rates were 68.8% for diclofenac, 59.8% for nabumetone, 67.6% for meloxicam and 69.1% for celecoxib.

Conclusions: Adverse drug reactions and their related withdrawals occurred mostly at an early stage of NSAID treatment, so it is crucial to strengthen pharmacovigilance during this period. Among the investigated NSAIDs, celecoxib did not prove to be superior to diclofenac, nabumetone or meloxicam with respect to its efficacy in the treatment of rheumatoid arthritis; however, it did show good patient compliance and safety profiles.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Table II
Fig. 2
Table III
Table IV
Table V
Fig. 3

Similar content being viewed by others

Notes

  1. Shanghai’s general hospitals are ranked as A, B and C class according to their patient-bed volume and service quality. A is the highest hospital category, each usually equipped with more than 1000 patient beds.

References

  1. Hawkey CJ. COX-1 and COX-2 inhibitors. Best Pract Res Clin Gastroenterol 2001; 15(5): 801–20

    Article  PubMed  CAS  Google Scholar 

  2. Marie R, Griffin MD. Epidemiology of non-steroidal anti-inflammatory drug-associated gastrointestinal injury. Am J Med 1998; 104(3A): 23–8

    Google Scholar 

  3. Arnet FC, Edworthy SM, Bloch DA. The American Rheumatoid Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1998; 31: 315–7

    Article  Google Scholar 

  4. Felson DT, Andersson JJ, Bores M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727–35

    Article  PubMed  CAS  Google Scholar 

  5. Rovensky J, Micekova D. Six-month prospective study to monitor the treatment of rheumatic disease with sustained-release flubiprofen. Drugs Exp Clin Res 2000; 26(1): 19–24

    PubMed  CAS  Google Scholar 

  6. Huskinsson EC, Ghozlan R, Kurthen R. A long-term study to evaluate the safety and efficacy of meloxicam therapy in the patients with rheumatoid arthritis. Br J Rheumatol 1996; 35Suppl. 1: 29–34

    Article  Google Scholar 

  7. Jones CW. A post-marketing surveillance study of Voltarol 75mg SR in the primary case setting. Br J Clin Pract 1995; 50: 390–5

    Google Scholar 

  8. Tindall EA, Sharp JT, Burr A, et al. A 12-month, multicenter, prospective, open-label trial of radiographic analysis of disease progression in osteoarthritis of the knee or hip in patients receiving celecoxib. Clin Ther 2002; 24(12): 2051–63

    Article  PubMed  Google Scholar 

  9. Emery P, Zeidler H, Kvien TK, et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomised double-blind comparison. Lancet 1999; 354(9196): 2106–11

    Article  PubMed  CAS  Google Scholar 

  10. Shi W, Wang YM, Cheng NN, et al. Meta-analysis on the effect and adverse reaction of NS AIDs treating patients with osteoarthritis and rheumatoid arthritis. Chinese J Epidemiol 2003; 24(11): 1044–8

    Google Scholar 

  11. Shi W, Wang YM, Cheng NN, et al. Sample size determination in a cohort study on NSAID adverse reactions. Chinese J Clin Pharmacol 2002; 18(6): 455–7

    Google Scholar 

  12. Lister BJ, Poland M, DeLapp RE. Efficacy of nabumetone versus diclofenac, naproxen, ibuprofen, and piroxicam in osteoarthritis and rheumatoid arthritis. Am J Med 1993; 95(2A): 2S–9S

    Article  PubMed  CAS  Google Scholar 

  13. Wordsworth BP. Rheumatoid arthritis. In: Weatherall DJ, Ledingham JGG, Warrell DA, editors. Oxford textbook of medicine: rheumatoid arthritis. New York: Oxford University Press, 1996: 2964

    Google Scholar 

  14. Weinblatt ME. Treatment of rheumatoid arthritis. In: Willian JK, editor. Arthritis and allied conditions, a textbook of rheumatology: rheumatoid arthritis. Baltimore (MD): Williams & Wilkins, 1997: 1134

    Google Scholar 

  15. Ahmad SR, Kortepeter C, Brinker A, et al. Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf 2002; 25(7): 537–44

    Article  PubMed  CAS  Google Scholar 

  16. Gurkirpal S. Recent considerations in nonsteroidal anti-inflammatory drug gastropathy. Am J Med 1998; 105: 31–38s

    Article  Google Scholar 

  17. Huskinsson EC, Ghozlan R, Kurthen R. A long-term study to evaluate the safety and efficacy of meloxicam therapy in the patients with rheumatoid arthritis. Br J Rheumatol 1996; 35Suppl. 1: 29–34

    Article  Google Scholar 

  18. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomized controlled trials. BMJ 2002; 325(7365): 619–24

    Article  PubMed  CAS  Google Scholar 

  19. Lanas A. Clinical experience with cyclooxygenase-2 inhibitors. Rheumatology (Oxford) 2002; 41Suppl. 1: 16–22

    Article  CAS  Google Scholar 

Download references

Acknowledgements

We thank the participating rheumatologists for their invaluable cooperation. This survey was supported in part by a grant (BK-PJ-0301) from the State Food and Drug Administration of China. The authors have no conflicts of interest directly relevant to the content of this study.

Author information

Authors and Affiliations

  1. Department of Pharmacology, School of Pharmacy, Fudan University, Shanghai, China

    Wen Shi, Yong Ming Wang, Duan Li, Neng Neng Chen & Bin Yan Chen

  2. The Center for Drug Reevaluation and the Center for Adverse Drug Reaction Monitoring, State Food and Drug Administration, Beijing, China

    Li Shao Li & Min Yan

Authors
  1. Wen Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Yong Ming Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Li Shao Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Min Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Duan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Neng Neng Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Bin Yan Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wen Shi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shi, W., Wang, Y.M., Li, L.S. et al. Safety and Efficacy of Oral Nonsteroidal Anti-Inflammatory Drugs in Patients with Rheumatoid Arthritis. Clin. Drug Investig. 24, 89–101 (2004). https://doi.org/10.2165/00044011-200424020-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00044011-200424020-00004

Keywords

Search

Navigation